Public Employees Retirement Association of Colorado Has $1.55 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Public Employees Retirement Association of Colorado grew its stake in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 58.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,003 shares of the medical research company’s stock after buying an additional 7,724 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Exact Sciences were worth $1,554,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of EXAS. Oppenheimer & Co. Inc. grew its holdings in shares of Exact Sciences by 4.7% during the fourth quarter. Oppenheimer & Co. Inc. now owns 22,687 shares of the medical research company’s stock worth $1,678,000 after buying an additional 1,020 shares in the last quarter. Capital World Investors grew its stake in shares of Exact Sciences by 7.8% during the 4th quarter. Capital World Investors now owns 7,468,145 shares of the medical research company’s stock worth $552,493,000 after acquiring an additional 539,498 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Exact Sciences by 8.5% during the 4th quarter. Armistice Capital LLC now owns 771,821 shares of the medical research company’s stock worth $57,099,000 after acquiring an additional 60,301 shares in the last quarter. Eisler Capital UK Ltd. acquired a new stake in shares of Exact Sciences in the fourth quarter valued at approximately $532,000. Finally, Royal London Asset Management Ltd. lifted its position in shares of Exact Sciences by 3.0% in the fourth quarter. Royal London Asset Management Ltd. now owns 70,418 shares of the medical research company’s stock worth $5,210,000 after purchasing an additional 2,040 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Citigroup cut their price target on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. TheStreet lowered Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Canaccord Genuity Group cut their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Jefferies Financial Group initiated coverage on shares of Exact Sciences in a report on Monday, June 3rd. They set a “buy” rating and a $75.00 target price on the stock. Finally, BTIG Research cut their price target on shares of Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.07.

Check Out Our Latest Research Report on EXAS

Insider Activity at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now directly owns 71,787 shares of the company’s stock, valued at approximately $5,025,090. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the transaction, the chief executive officer now owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The disclosure for this sale can be found here. Insiders sold a total of 5,498 shares of company stock valued at $370,105 in the last quarter. Insiders own 1.36% of the company’s stock.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $42.89 on Tuesday. The firm has a 50 day moving average of $58.36 and a 200-day moving average of $62.56. Exact Sciences Co. has a 12 month low of $42.26 and a 12 month high of $100.77. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $7.91 billion, a PE ratio of -32.49 and a beta of 1.26.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. The company had revenue of $637.52 million during the quarter, compared to analysts’ expectations of $624.95 million. On average, equities research analysts predict that Exact Sciences Co. will post -1.15 EPS for the current fiscal year.

Exact Sciences Company Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Recommended Stories

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.